(Reuters) - Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback